lapatinib has been researched along with letrozole in 37 studies
Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (letrozole) | Trials (letrozole) | Recent Studies (post-2010) (letrozole) |
---|---|---|---|---|---|
1,919 | 305 | 1,442 | 2,612 | 612 | 1,602 |
Protein | Taxonomy | lapatinib (IC50) | letrozole (IC50) |
---|---|---|---|
Steryl-sulfatase | Homo sapiens (human) | 0.0009 | |
Aromatase | Homo sapiens (human) | 0.009 | |
Cytochrome P450 11B1, mitochondrial | Homo sapiens (human) | 2.62 | |
Cytochrome P450 11B2, mitochondrial | Homo sapiens (human) | 1.42 | |
Amine oxidase [flavin-containing] A | Rattus norvegicus (Norway rat) | 0.0009 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (13.51) | 29.6817 |
2010's | 27 (72.97) | 24.3611 |
2020's | 5 (13.51) | 2.80 |
Authors | Studies |
---|---|
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F | 1 |
Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK | 1 |
Fricker, J | 1 |
Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S | 1 |
Guarneri, V | 1 |
Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS | 1 |
Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S | 1 |
Curran, MP | 1 |
Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B | 2 |
Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL | 1 |
de Azambuja, E; Metzger-Filho, O | 1 |
Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N | 1 |
Ito, Y | 1 |
Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R | 1 |
Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T | 1 |
Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT | 1 |
Mehta, A; Tripathy, D | 1 |
Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF | 1 |
Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E | 1 |
Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP | 1 |
Harbeck, N | 1 |
Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L | 1 |
Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M | 1 |
Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
Yamamoto, C; Yamamoto, D; Yamamoto, M | 1 |
Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F | 1 |
De Angelis, C; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Jiralerspong, S; Krop, I; Nanda, R; Nangia, JR; Niravath, P; Osborne, CK; Pavlick, A; Rexer, BN; Rimawi, MF; Schiff, R; Storniolo, AM; Veeraraghavan, J; Wang, T; Wolff, AC | 1 |
Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, D; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH | 1 |
Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC | 1 |
Acconcia, F | 1 |
Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL | 1 |
11 review(s) available for lapatinib and letrozole
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
[Management of metastatic HER2-positive breast cancer: present and future].
Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2010 |
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles | 2011 |
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2011 |
[Progress of molecularly targeted therapy for breast cancer].
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2012 |
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles | 2012 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States | 2014 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
12 trial(s) available for lapatinib and letrozole
Article | Year |
---|---|
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles | 2008 |
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles | 2008 |
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles | 2009 |
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2010 |
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles | 2010 |
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles | 2011 |
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles | 2013 |
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2014 |
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles | 2016 |
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult | 2020 |
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
Topics: Aged; Biomarkers, Tumor; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Progression-Free Survival; Receptor, ErbB-2; Tumor Suppressor Protein p53 | 2020 |
14 other study(ies) available for lapatinib and letrozole
Article | Year |
---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
San Antonio Breast Cancer Symposium.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid | 2009 |
Breast cancer drug approved for new indication.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health | 2010 |
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles | 2011 |
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles | 2014 |
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles | 2015 |
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles | 2016 |
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles | 2016 |
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles | 2016 |
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles | 2017 |
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pterocarpans; Triazoles | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Mitogen-Activated Protein Kinases; Nitriles; Triazoles | 2023 |